Board of Directors

Doug Morton, PhD (Chairman of the Board)

Dr. Doug Morton serves as Chairman of the Board at Renovo Neural. He is presently a consultant in the life sciences, working with a variety of for-profit and non-profit organizations. From 2003-2006, he was CEO, Southwest Michigan Innovation Center, an incubator/accelerator located in Kalamazoo that provides wet-laboratory space, access to venture funding, and business services to emerging companies in the life sciences arena. Since 2006, he has continued his involvement with the Center as a member of its Managing Directors group. Doug spent the majority of his career in the pharmaceutical industry, joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn’s subsequent mergers until 2003 when he worked as Group Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation. In this position, he was responsible for technology acquisition and operations for worldwide Discovery Research throughout Pharmacia. Doug holds an A.B. degree in Chemistry from Kenyon College and a PhD degree in Organic Chemistry from Columbia University. He completed postdoctoral studies in organic chemistry at Stanford University. Doug has served on the Board of Directors of TissueInformatics, Inc. from May 2003 until the closing of Paradigm Genetics’ acquisition of the company in March 2004. He served as a member of the Board of Directors of Icoria, Inc. (formerly Paradigm Genetics, Inc.) since March 2004 until the acquisition of the Company by Clinical Data, Inc. in December 2005. He also served as Interim CEO of Icoria since April 2005 until the close of the acquisition with Clinical Data. Doug is currently a member of the Industrial Advisory Board of Cleveland Clinic Foundation Innovations, a member of the Scientific Advisory Board and Management Committee of the Southwest Michigan First Life Science Fund, and chairman of the Scientific Advisory Boards of Hopen Therapeutics and Metabolic Solutions Development Company. Doug is also a board member of NephRx Corporation, TCH Pharmaceuticals, Inc., and Tolera Therapeutics, Inc.


Satish Medicetty, MBA, PhD

Dr. Satish Medicetty served as Renovo’s President, CEO, and Board Director beginning in May 2010. He spearheaded the development and commercialization of preclinical assays and animal models at Renovo. He was instrumental in establishing Renovo as a specialized neuro-CRO. In addition, he has also overseen the early stage drug discovery efforts at Renovo. In May 2016, Dr. Medicetty began his role as President of GTCbio while remaining to serve on as Board Director for Renovo. He founded Neurotherapies LLC in June 2016 and worked as Director of Stem Cell Research and Lab Operations at NeoStem Inc. as well as a Senior Scientist at Athersys before his time with Renovo. Dr. Medicetty holds a BVSc in Veterinary Medicine from Acharya N.G. Ranga Agricultural University and PhD from Kansas State University and an MBA at Case Western Reserve University’s Weatherhead School of Management.


Tina Rodgers, MBA, PhD
Dr. Tina Rodgers joined Renovo’s Board of Directors in July 2012 bringing her expertise in early drug development in the CRO industry. Before her time at Renovo, Dr. Rodgers worked for the University of Alabama at Birmingham as Manager of the MAMDS FACS Core Facility and for Southern Research Institute as VP of Drug Development. She held several positions at MPI Research, including Associate Director of Research, Executive VP and Director of Research, and CSO/VP of Strategic Accounts. Dr. Rodgers is founder of Midwest Life Science Advisors LLC and served as CEO of the company before taking on a role as Executive Director of Safety Assessment at SNBL USA, quickly moving into her current position as VP of Preclinical Sciences. Additionally, she has served on the Board of Directors for MichBio and is actively involved in the Institutional Biosafety Committee at the University of Washington. Dr. Rodgers received her BA degree in French and Biology from Birmingham-Southern College and pursued a PhD in Molecular and Cellular Biology and Pathobiology at the Medical University of South Carolina/ She later received her MBA in Management from Auburn University.


Joe Rich, MBA, JD
Joe Rich joined Renovo’s Board of Directors, bringing his expertise in implementing strategic plans, budgets, financial reviews and governance. Joe currently serves as Senior Innovations Officer of New Ventures at the Cleveland Clinic. Before his time at the Cleveland Clinic, Joe was involved in legal affairs at the University of Akron with a role as Commercialization Manager followed by a position as VP and General Counsel of the university’s Research Foundation. Joe holds a BS in Biology from John Carroll University and a JD as well as an MBA in Finance from the University of Akron.